EuroMedtech™ 2012 in Grenoble spurs collaborations among a diversity of medtech players
Leaders from the medtech industry gathered last week for the fourth annual EuroMedtech™ partnering conference held in Grenoble, France, May 31–June 1, 2012 at the Convention Center of the WTC Grenoble. 306 delegates representing 206 companies from 24 countries engaged in 755 one-to-one partnering meetings, confirming EuroMedtech as the premier destination for forming partnerships between emerging innovator and start-up companies, and large multinational firms.
“EuroMedtech 2012 was another dynamic event that saw a high level of engagement between large medtech companies and emerging innovators, as well as between traditional and non-traditional firms operating in the sector,” said Carola Schropp, President of EBD Group. “Despite continuing economic headwinds, medtech has much to be optimistic about. From advances in cardiovascular and orthopedics, to improving regulatory processes, the medtech industry has fundamentals pointing in the right direction.”
Hosts ADEBAG and CCI Grenoble brought together an impressive mix of companies, partners and local authorities at EuroMedtech including Becton Dickinson, bioMérieux, Roche Diagnostics, Cabinet Regimbeau, Minitubes, Trixell, AEPI, Banque Populaire des Alpes, Institut fédératif de Recherche Santé et Société, LETI Health, Minalogic, UBIFRANCE, I-Care, Conseil Général de l’Isère, Entreprise Europe Network, Grenoble Alpes Métropole, Région Rhône-Alpes and Ville de Grenoble.
“ADEBAG was pleased to bring EuroMedtech to the Grenoble-Isere region this year. Delegates representing a wide spectrum of biotech device and medical technology companies benefited from the opportunities for international collaboration,” said Cécile Real, President of ADEBAG. “New efficient technologies and less invasive treatments are the future of progressive healthcare, and partnerships are the way we are going to see this innovation reach the patient.”
“Innovation networks are critical to advancing healthcare solutions,” said John Vaylet, president of CCI Grenoble, “and EuroMedtech was highly conducive to our companies identifying new opportunities for mutually beneficial partnerships. Networking and synergism between local and foreign actors, between research, industry and education, are deeply inscribed in the DNA of Grenoble and this was very well highlighted during this event.”
The plenary session, “State of the industry: Innovation sources and industry dynamics,” moderated by Regina Hodits of Wellington Partners, was excellent and very provocative. Panelists Angelo De Rosa of Medtronic; Charles Knowles of Queen Mary University London; and Josep Ll. Sanfeliu of Ysios Capital Partners discussed current trends and sources of innovation in the medtech industry.
The neuromodulation session, moderated by Karl Schweitzer of Medtronic, was extremely interesting, with Stéphan Chabardes of Clinique de Neurochirurgie CHU de Grenoble showing videos of drastically improved outcomes from the now-routine applications of Deep Brain Stimulation (DBS), and valuable commentary from Sjaak Deckers of Sapiens.
Another program highlight was the telehealthcare panel moderated by Thom Rasche of Earlybird Venture Capital with panelists Marc Attia of Movea and Patrick Blouet of ST-Ericsson. “The OR of the future,” moderated by Sigal Weisswasser of The T.B.N. Group, was also well attended and featured Professor Alim Benabid of CEA Clinatec, discoverer of DBS, with Rubi Halberthal of Haldor Advanced Technologies and Clément Vidal of EndoControl.
“The session focused on new developments in augmented medicine and cutting edge surgical tools. It was well moderated and dynamic and stimulated a good discussion,” said Vidal, CEO and President of EndoControl.
Presenting company highlights included the Large Corporation track, the Medicon Valley track, the local Medic@lps track and the Torino track hosted by Italian cluster BioPmed.
The Grenoble event rounded up with an evening reception at the Musée de Grenoble that featured fantastic food and a vibrant, positive atmosphere.
EuroMedtech is Europe’s leading medical technology partnering conference, providing collaboration opportunities to medtech decision makers and investors. EuroMedtech caters to companies involved in all parts of the advanced medical technology industry, from those serving mainline therapeutic categories such as orthopedics and neurology, through diagnostics, imaging and eHealth, to those involved in platform technologies such as biomaterials and augmented medicine. Also attending are companies serving the industry, such as manufacturers, law firms, CROs and distributors.
EuroMedtech featured EBD Group’s sophisticated, web-based partnering system, partneringONE®, the event enables delegates to efficiently identify, meet and do business with attending companies, from large international medtech companies and just launched start-ups, to venture capitalists and private equity firms.
Grenoble is a key center of excellence and a thriving life science hub, and is the eleventh largest city in France with a population of 600,000. Grenoble also boasts the ninth largest university complex in France. The healthcare industry accounts for more than EUR 4.1 billion in turnover and over 8,500 jobs. The city also has over 200 public laboratories and four key international research equipment facilities. MEDIC@LPS, the Grenoble Health Cluster, is a key player in the promotion of Grenoble’s bioindustry sector and a co-host of EuroMedtech 2012.
Post-event coverage for EuroMedtech 2012 can be found at www.ebdgroup.com/emt.
Additional links and information:
For more coverage on EuroMedtech 2012, go to www.ebdgroup.com/emt.
Follow EuroMedtech 2012 posts on Twitter: twitter.com/EuroMedtech (hashtag: #EMT12)
LinkedIn Event site: http://linkd.in/vCy2Db
About EBD Group
EBD Group is the leading partnering firm for the global life science industry. Since 1993, biotech, pharma and medical device companies have leveraged EBD Group’s partnering conferences, technology and services to identify business opportunities and develop strategic relationships essential to their success.
EBD Group’s conferences are run with the support of leading corporations and international trade associations and include:
- BIO-Europe® and BIO-Europe Spring®, Europe’s largest life science partnering conferences, supported by the Biotechnology Industry Organization (BIO)
- BioPharm America™, the fastest growing partnering event in North America
- Biotech Showcase™, a unique forum in San Francisco for presenting to investors and business development executives, co-produced with Demy-Colton Life Science Advisors
- BioEquity Europe, the investor conference co-organized with BioCentury Publications and BIO
- ChinaBio® Partnering Forum, the first dedicated biotech/pharma partnering conference in China, co-produced with ChinaBio® LLC
- EuroMedtech™, EBD Group’s partnering event for the innovative medical technology industry
- The Global Impact Forum™, a unique and innovative partnering conference in impact investing and venture philanthropy.
EBD Group’s sophisticated web-based partnering service, partneringONE®, is used as the partnering engine at numerous third-party events around the world, and partnering360® is the open online community of life science dealmakers that enhances partnering experiences throughout the year.
EBD Group is an Informa company. Informa is the largest publicly-owned organizer of exhibitions, conferences and training in the world.
EBD Group has offices in the USA and Europe.
For more information please visit www.ebdgroup.com.